Inhibitors of sodium glucose cotransporter 1
View Patent ↗Inhibitors of sodium glucose cotransporter 1 (SGLT1), compositions comprising them, and methods of their use to treat diseases and disorders such as diabetes are disclosed. Particular compounds are of the formula: the various substituents of which are defined herein.
1. A compound, which is N-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oxopropan-2-yl)-4-(4-(2-methyl-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)benzyl)phenyl)butanamide:
or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable excipient or diluent.
3. A solid oral dosage form comprising the pharmaceutical composition of claim 2 .
4. The solid oral dosage form of claim 3 , which is a tablet.
5. The solid oral dosage form of claim 3 , which is a capsule.
6. A method of treating or managing diabetes, which comprises administering to a patient in need thereof a therapeutically effective amount of N-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oxopropan-2-yl)-4-(4-(2-methyl-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)benzyl)phenyl)butanamide:
or a pharmaceutically acceptable salt thereof.
7. The method of claim 6 , wherein the diabetes is type 1 diabetes.
8. The method of claim 6 , wherein the diabetes is type 2 diabetes.